REXAHN PHARMACEUTICALS, INC. 4
4 · REXAHN PHARMACEUTICALS, INC. · Filed Jan 14, 2014
Insider Transaction Report
Form 4
Suzdak Peter David
Chief Executive Officer
Transactions
- Award
Stock Option (right to purchase)
2014-01-12+350,000→ 350,000 totalExercise: $1.14Exp: 2024-01-12→ Common Stock (350,000 underlying)
Holdings
- 1,200,000
Stock Option (right to purchase)
Exercise: $0.37From: 2013-02-04Exp: 2023-02-04→ Common Stock (1,200,000 underlying)
Footnotes (1)
- [F1]Options will vest and be exercisable based on the following schedule: 105,000 on January 12, 2015, 105,000 on January 12, 2016, and 140,000 on January 12, 2017.